{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:14:53Z","timestamp":1707524093056},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,21]]},"DOI":"10.7759\/cureus.8743","type":"journal-article","created":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T14:26:32Z","timestamp":1592749592000},"source":"Crossref","is-referenced-by-count":0,"title":["Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma"],"prefix":"10.7759","author":[{"given":"Clifford B","family":"Locke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Lansigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"9","author":"Caron F","year":"2017","unstructured":"Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017, 9:772-8. 10.1182\/bloodadvances.2016001883","journal-title":"Blood Adv"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis","volume":"184","author":"Brown JR","year":"2019","unstructured":"Brown JR, Moslehi J, Ewer MS, et al.. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019, 184:558-69. 10.1111\/bjh.15690","journal-title":"Br J Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"8","author":"Wang ML","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al.. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013, 8:507-16. 10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang ML","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, et al.. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015, 126:739-45. 10.1182\/blood-2015-03-635326","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato AR","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, et al.. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018, 103:874-9. 10.3324\/haematol.2017.182907","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel JJ","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost JTH. 2017, 15:835-47. 10.1111\/jth.13651","journal-title":"J Thromb Haemost JTH"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of major bleeding with ibrutinib","volume":"18","author":"Mock J","year":"2018","unstructured":"Mock J, Kunk PR, Palkimas S, et al.. Risk of major bleeding with ibrutinib. Clin Lymphoma Myeloma Leuk. 2018, 18:755-61. 10.1016\/j.clml.2018.07.287","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE- 17): a phase 2, open-label, multicentre study","volume":"1","author":"O\u2019Brien S","year":"2016","unstructured":"O\u2019Brien S, Jones JA, Coutre SE, et al.. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE- 17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016, 1:1409-18. 10.1016\/S1470-2045(16)30212-1","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"21","author":"Dimopoulos MA","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, et al.. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018, 21:2399-410. 10.1056\/NEJMoa1802917","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2387","article-title":"Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma","volume":"36","author":"Kreiniz N","year":"2018","unstructured":"Kreiniz N, Bejar J, Polliack A, Tadmor T. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. Hematol Oncol. 2018, 36:349-54. 10.1002\/hon.2387","journal-title":"Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling M","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, et al.. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet Lond Engl. 2016, 387:770-8. 10.1016\/S0140-6736(15)00667-4","journal-title":"Lancet Lond Engl"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler CH","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, et al.. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008, 112:2687-93. 10.1182\/blood-2008-03-147025","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"29","author":"Tam CS","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, et al.. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018, 29:1211-23. 10.1056\/NEJMoa1715519","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-460162","article-title":"Treatment of cancer-associated thrombosis","volume":"122","author":"Lee AYY","year":"2013","unstructured":"Lee AYY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013, 122:2310-7. 10.1182\/blood-2013-04-460162","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2084","article-title":"Diffuse alveolar hemorrhage","volume":"137","author":"Lara AR","year":"2010","unstructured":"Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010, 137:1164-71. 10.1378\/chest.08-2084","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2012.e11","article-title":"Pulmonary mantle cell lymphoma: a rare manifestation of an uncommon condition","volume":"4","author":"DePew ZS","year":"2012","unstructured":"DePew ZS, Vassallo R. Pulmonary mantle cell lymphoma: a rare manifestation of an uncommon condition. Rare Tumors. 2012, 4:e11. 10.4081\/rt.2012.e11","journal-title":"Rare Tumors"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib","volume":"178","author":"Jones JA","year":"2017","unstructured":"Jones JA, Hillmen P, Coutre S, et al.. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017, 178:286-91. 10.1111\/bjh.14660","journal-title":"Br J Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/32185-diffuse-alveolar-hemorrhage-secondary-to-ibrutinib-therapy-in-a-patient-with-refractory-mantle-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:43Z","timestamp":1707506803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/32185-diffuse-alveolar-hemorrhage-secondary-to-ibrutinib-therapy-in-a-patient-with-refractory-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,21]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.8743","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,21]]}}}